The US Food and Drug Administration (FDA) announced late last week that it has suspended the license for French drugmaker Valneva's chikungunya vaccine, saying that continued administration of the vaccine to the public would pose a danger to health.

The agency said it had become aware of more reports of serious adverse events, leading center director Vinay Prasad to conclude the vaccine is no longer safe for its intended use.

The United States Food and Drug Administration (FDA) has suspended the licence of one of the two chikungunya vaccines available in the country, following chikungunya-like illness in recipients of the shot.